He was Chief Scientific Advisor to BioAegis Therapeutics Inc., a clinical-stage biotech company developing a non-immunosuppressive anti-inflammatory with the potential to address a wide range of infectious, inflammatory, and degenerative diseases.

Gelsolin is also an abundant extracellular protein that circulates in blood plasma, and Stossel established that it is a component of innate immunity that promotes host antimicrobial activity and prevents the potentially lethal dissemination of inflammation.

[citation needed] His company, BioAegis Therapeutics, is conducting clinical trials to assess the potential of plasma gelsolin therapy in a wide variety of infectious, inflammatory, and degenerative diseases.

[3] Tom Stossel was co-founder and chief scientific advisor to BioAegis, a clinical stage company focused on developing therapies for infectious, inflammatory, and degenerative diseases through a portfolio built around plasma gelsolin technology and therapeutics.

pGSN is a master regulator—a key immune modulator that balances the inflammatory process to prevent the spread of excess inflammation while simultaneously enhancing antimicrobial defense.

Stossel was the author of almost 300 publications, including co-authoring two textbooks, Haematology: A Pathophysiological Approach (1984) and Blood: Principles and Practice of Hematology (1997), and the consumer book Pharmaphobia: How the Conflict of Interest Myth Undermines American Medical Innovation (2015).

[5] Stossel was a co-founder of Options for Children in Zambia, which provides dental and medical preventive care and other services to the country's major teaching hospital, an orphanage, and remote rural villages.